Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Operating Leases: 2019-2024

Historic Operating Leases for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $60.0 million.

  • C4 Therapeutics' Operating Leases fell 10.11% to $55.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.2 million, marking a year-over-year decrease of 10.11%. This contributed to the annual value of $60.0 million for FY2024, which is 8.78% down from last year.
  • As of FY2024, C4 Therapeutics' Operating Leases stood at $60.0 million, which was down 8.78% from $65.8 million recorded in FY2023.
  • C4 Therapeutics' Operating Leases' 5-year high stood at $71.0 million during FY2022, with a 5-year trough of $11.8 million in FY2020.
  • Moreover, its 3-year median value for Operating Leases was $65.8 million (2023), whereas its average is $65.6 million.
  • Per our database at Business Quant, C4 Therapeutics' Operating Leases spiked by 160.25% in 2021 and then fell by 8.78% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Operating Leases stood at $11.8 million in 2020, then skyrocketed by 160.25% to $30.8 million in 2021, then skyrocketed by 130.59% to $71.0 million in 2022, then dropped by 7.35% to $65.8 million in 2023, then fell by 8.78% to $60.0 million in 2024.